2007
DOI: 10.1158/1078-0432.ccr-07-0718
|View full text |Cite
|
Sign up to set email alerts
|

Reply to the Letter to the Editor from Schultes et al

Abstract: In Response: We wish to thank Drs. Schultes, Smith, and Nicodemus for their questions about our characterization of oregovomab as passive immunotherapy, the potential interference of human anti-mouse antibody (HAMA) in the Luminex assay used in our studies, and clarification on the induction of CA125-specific B-and T-cell responses (1).(a) We agree that published studies indicate that oregovomab is capable of inducing CA125-specific immune responses via the idiotypic network and cross-presentation (2, 3). We w… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 6 publications
0
4
0
Order By: Relevance
“…Ulimorelin, described as a ghrelin receptor agonist (pK i 7.8 and pD 2 7.5 at human recombinant ghrelin receptors), has been shown to stimulate ghrelin receptor mediated food intake and gastric emptying but not elicit release of growth hormone, or modify ghrelin stimulated growth hormone release, thus pharmacolog-ically discriminating the orexigenic and gastrointestinal actions of ghrelin (GHRL, Q9UBU3) from the release of growth hormone [622]. A number of selective antagonists have been reported, including peptidomimetic [1514] and non-peptide small molecules including GSK1614343 [1684,1848].…”
Section: G Protein-coupled Receptors → Ghrelin Receptormentioning
confidence: 99%
“…Ulimorelin, described as a ghrelin receptor agonist (pK i 7.8 and pD 2 7.5 at human recombinant ghrelin receptors), has been shown to stimulate ghrelin receptor mediated food intake and gastric emptying but not elicit release of growth hormone, or modify ghrelin stimulated growth hormone release, thus pharmacolog-ically discriminating the orexigenic and gastrointestinal actions of ghrelin (GHRL, Q9UBU3) from the release of growth hormone [622]. A number of selective antagonists have been reported, including peptidomimetic [1514] and non-peptide small molecules including GSK1614343 [1684,1848].…”
Section: G Protein-coupled Receptors → Ghrelin Receptormentioning
confidence: 99%
“…Ulimorelin, described as a ghrelin receptor agonist (pK i 7.8 and pD 2 7.5 at human recombinant ghrelin receptors), has been shown to stimulate ghrelin receptor mediated food intake and gastric emptying but not elicit release of growth hormone, or modify ghrelin stimulated growth hormone release, thus pharmacologically discriminating the orexigenic and gastrointestinal actions of ghrelin (GHRL, Q9UBU3) from the release of growth hormone [567]. A number of selective antagonists have been reported, including peptidomimetic [1393] and non-peptide small molecules including GSK1614343 [1556,1699]. Glucagon receptor family…”
Section: Overviewmentioning
confidence: 99%
“…Similar discrimination of ghrelin receptor mediated physiological functions can be obtained by activation of distinct signaling pathways [1562]. A number of selective antagonists have been reported, including peptidomimetic [1658] and non-peptide small molecules including GSK1614343 [1831,1847,2037].…”
Section: Further Reading On Ghrelin Receptormentioning
confidence: 99%